{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:22:36Z","timestamp":1762899756507,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":654,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1136\/esmoopen-2019-000515","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T07:15:28Z","timestamp":1558509328000},"page":"e000515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Neoadjuvant treatment for intermediate\/high-risk HER2-positive and triple-negative breast cancers: no longer an \u2018option\u2019 but an ethical obligation"],"prefix":"10.1016","volume":"4","clinical-trial-number":[{"clinical-trial-number":"nct01864746","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02954874","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01953588","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01779206","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-3544","authenticated-orcid":false,"given":"Mariana","family":"Brand\u00e3o","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-3589","authenticated-orcid":false,"given":"Fabien","family":"Reyal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-3022","authenticated-orcid":false,"given":"Anne-Sophie","family":"Hamy","sequence":"additional","affiliation":[]},{"given":"Martine","family":"Piccart-Gebhart","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000515_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000371","article-title":"Neoadjuvant treatment: the future of patients with breast cancer","volume":"3","author":"Reyal","year":"2018","journal-title":"ESMO Open"},{"key":"10.1136\/esmoopen-2019-000515_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","author":"Asselain","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000515_bb0020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","article-title":"Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis","volume":"269","author":"Simons","year":"2019","journal-title":"Ann Surg"},{"key":"10.1136\/esmoopen-2019-000515_bb0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2019-000515_bb0030","volume":"79","author":"Spring","year":"2019","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2019-000515_bb0035","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000515_bb0040","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1200\/JCO.2018.78.8604","article-title":"Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update","volume":"36","author":"Denduluri","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000515_bb0045","article-title":"NCCN clinical practice guidelines in oncology","volume":"215","author":"Gradishar","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1136\/esmoopen-2019-000515_bb0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000515_bb0055","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000515_bb0060","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2019-000515_bb0065","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000515_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1136\/esmoopen-2019-000515_bb0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2018.09.012","article-title":"Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapy","volume":"132","author":"Taourel","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/esmoopen-2019-000515_bb0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.clbc.2016.12.010","article-title":"Role of magnetic resonance imaging in detection of pathologic complete remission in breast cancer patients treated with neoadjuvant chemotherapy: a meta-analysis","volume":"17","author":"Gu","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1136\/esmoopen-2019-000515_bb0085","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2967\/jnumed.112.119271","article-title":"18F-FDG PET\/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO","volume":"54","author":"Gebhart","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1136\/esmoopen-2019-000515_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01524-7","article-title":"Metabolic Radiomics for pretreatment 18F-FDG PET\/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neoadjuvant chemotherapy, and prognosis","volume":"7","author":"Ha","year":"2017","journal-title":"Sci Rep"},{"key":"10.1136\/esmoopen-2019-000515_bb0095","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","article-title":"NeoPalAna: neoadjuvant Palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2019-000515_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz055","article-title":"De-escalated therapy for HR+\/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study","author":"Guarneri","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000515_bb0105","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/annonc\/mdx494","volume":"28","author":"Nitz","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000515_bb0110","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2016.71.9815","volume":"35","author":"Harbeck","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000515_bb0115","doi-asserted-by":"crossref","first-page":"86423","DOI":"10.18632\/oncotarget.21198","article-title":"Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2019-000515_bb0120","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1373\/clinchem.2016.262337","article-title":"Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer","volume":"63","author":"Riva","year":"2017","journal-title":"Clin Chem"},{"issue":"suppl 5","key":"10.1136\/esmoopen-2019-000515_bb0125","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000515_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2718","article-title":"Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women","volume":"344","author":"Kesson","year":"2012","journal-title":"BMJ"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920301551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920301551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:11Z","timestamp":1761855731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920301551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"alternative-id":["S2059702920301551"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000515","relation":{},"ISSN":["2059-7029"],"issn-type":[{"type":"print","value":"2059-7029"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant treatment for intermediate\/high-risk HER2-positive and triple-negative breast cancers: no longer an \u2018option\u2019 but an ethical obligation","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000515"}}